(MENAFNEditorial) NEW YORK, NY / ACCESSWIRE / August 21, 2017 / Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has initiated coverage of Orgenesis Inc. (OTCQB: ORGS). The in-depth 20-page initiation report includes detailed information on Orgenesis' business model, services, industry, valuation, management and risks.
The full research report is available . Highlights from the report include:
Large Market Opportunity
Orgenesis Inc. offers investors a way to invest in the growing cell therapy market, with the regenerative medicine market projected to reach $53.7 billion by 2021, without the risk of investing in one specific cell therapy company, which generally have highly volatile, binomial investment outcomes. By investing in Orgenesis, investors own a share of the diversified revenue generated by Orgenesis' growing customer base, while still benefiting from large upside if its customers' products are successful via exponentially larger contract revenue.
Innovative Diabetes Treatment Technology
Backed by strong intellectual property, Orgenesis, through its subsidiary Orgenesis Ltd., has developed unique technologies with a lead indication for insulin-dependent diabetes, or type 1 diabetes. Orgenesis is currently developing a cellular approach directed at converting mature liver cells into functional glucose-responsive insulin-producing cells as a treatment for type 1 diabetes. Diabetes is one of the most challenging health problems of the 21st century and has immense economic and social costs.
Unique Financing Strategy
Orgenesis attractively finances its business through grants, private placements, local government support programs, and organic revenue from its growing CDMO business segment.
Based on Diamond Equity Research's financial valuation models, Orgenesis appears undervalued with numerous catalysts over the next 18 months.
About Orgenesis Inc.
Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. In addition, through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. This integrated approach supports Orgenesis's business philosophy of bringing to market significant life-improving medical treatments.
For more information, visit .
About Diamond Equity Research
Diamond Equity Research provides institutional quality research to emerging growth companies that are undercovered and undervalued. Diamond Equity Research is an approved sell-side provider on premier institutional investor platforms including Factset, Morningstar, and Thomson One. The founder, Hunter Diamond, CFA, brings extensive experience working as a research analyst and investment banker focused on emerging growth companies. Hunter Diamond holds his Bachelor of Science and Master of Business Administration from Cornell University. The firm is headquartered in Midtown Manhattan.
For more information, visit
Full disclosures pertaining to this report can be found in the report at . Orgenesis Inc. has paid for this report as company sponsored research, which is meant to subsidize the high cost of creating the report and monitoring the security. However, the views in the report reflect that of Diamond Equity. Diamond Equity Research LLC is being compensated by Orgenesis Inc. for producing research materials regarding Orgenesis Inc. and its securities. Payment is made in cash and is billed one time and upfront for a six-month subscription, which includes one initiation report and one update report. As of 08/21/2017, the issuer had paid us $10,000 for our services, which commenced 07/07/2017. Additional fees may have accrued since then.
Diamond Equity Research
SOURCE: Diamond Equity Research, LLC
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.